Xtalpi Holdings Limited · HKEX:2228
Xtalpi — H1 2024 Earnings Presentation
26 slides from Xtalpi's earnings presentation, August 2024
Slide 1: New Productive Forces to Drive Future Industry Development
New Productive Forces to Drive Future Industry Development QuantumPharm Inc. 1H2024 Investor Presentation
Slide 2: Disclaimer
THIS DOCUMENT IS FOR INFORMATIONAL PURPOSES ONLY AND IS NOT INTENDED TO BE, AND SHALL NOT BE CONSTRUED AS, AN OFFER, INDUCEMENT, INVITATION, SOLICITATION, COMMITMENT OR ADVERTISEMENT WITH RESPECT TO THE PURCHASE, SUBSCRIPTION OR SALE OF ANY SECURITY AND NO PART OF IT SHALL FORM THE BASIS OF, OR BE R
Slide 3: Our Journey: AI + Robotics to Establish New-Generation R&D Platform
Our Journey: AI + Robotics to Establish New-Generation R&D Platform 2014 - 2018 2018 - 2023 Since 2023 AI + Intelligent Robotics Data-Driven Quantum Physics Lab Domain Model Applied to small molecule drug discovery Combining chemistry experiments with new Empowering pharmaceuticals, energy drug R&D
Slide 4: AI + Robotics Across Industries Empower Drug and New Material Discovery
AI + Robotics Across Industries Empower Drug and New Material Discovery Medical and New Energy New Material Healthcare Full-Process Energy Carrier New Material R&D Drug R&D Development Biological and Chemical Biological and Chemical Drug Discovery Platform Synthesis Platform Synthesis Platform Quant
Slide 5: International Award for Intelligent and Automated Drug Discovery Platform
International Award for Intelligent and Automated Drug Discovery Platform Super AI Leader Award and "Key Highlights of the WAIC" at the 2023 World Artificial Intelligence Conference Confidential Copyright © 5 2024
Slide 6: The First Successful HKEX Chapter 18C Listing
The First Successful HKEX Chapter 18C Listing (QuantumPharm Inc., Stock Code: 2228.HK) Mr. Paul Chan Mo-po, Financial Secretary of the Hong Kong SAR, Mr. Sun Dong, Secretary for Innovation, Technology and Industry of the Hong Kong SAR Government, Ms. Cheong Man-lei, Under Secretary for Innovation, T
Slide 7: Over 300 Global Partners
Over 300 Global Partners Sanofi global executive team XtalPi and Lilly signed a US$250 XtalPi and Pfizer entered strategic visited XtalPi’s Shanghai Office million drug discovery agreement collaboration for AI-powered drug discovery and development Some of our global partners Confidential Copyright
Slide 8: 1H2024 Snapshot
1H2024 Snapshot In 1H24, we achieved cost reductions and efficiency improvements with adjusted net loss narrowing by 30% YoY RMB’ million 2024 2024 2023 FY23 FY22 FY21 1H 1H YOY 1H Revenue 103 28 % 80 174 133 63 R&D Expense 210 -10 % 234 481 359 213 Adjusted Net Loss -251 30 % -358 -522 -437 -217 Co
Slide 9: 1H2024 Business Highlights
3S xtal?i 1H2024 Business Highlights
Slide 10: 1H2024 Business Highlights Overview
1H2024 Business Highlights Overview Drug Discovery Solutions Intelligent Automation Solutions Customer Management • We continuously delivered satisfactory pipeline results to customers and consistently gained repeat business from them. “ Expanding AI+Automation R&D capabilities into more areas “ • W
Slide 11: Significant Progress on Pipelines
Significant Progress on Pipelines 1 Target Hypothesis Target to Hit Hit-to-Lead Lead Optimization Preclinical Phase I Phase II Phase III Partner Phase Indications Pipeline Characteristic/Differences Signet IND Diffuse gastric cancer • The world’s first innovative targeted drug integrating AI and org
Slide 12: New Progress in Globalization
New Progress in Globalization Europe Japan Middle S. Korea United States East 5. We have signed contracts with over 10 new overseas 1. In Apr 2024, our tumor vaccine program in customers, including large cooperation with CK Life Science was presented in a poster at the AACR in the U.S., Singapore mu
Slide 13: 1H2024 Highlights in Future Chemistry Platform
1H2024 Highlights in Future Chemistry Platform Accelerating the drug discovery process to create a “ digital, intelligent and automated future chemistry “ platform A U.S. leading MNC Technical Fundamentals – 1H Key R&D Focuses Validation of R&D Capabilities A European biotechnology Intelligence + In
Slide 14: Chemical Large Model – High-Quality Data Accelerates Algorithm Iteration
Chemical Large Model – High-Quality Data Accelerates Algorithm Iteration 2027+ Reverse reaction capability 2026 Achieve over 2M data capacity Automation capabilities covering all Coverage of most common reaction 20+ common reaction models and models 15 Reaction muti-step synthesis experiments Achiev
Slide 15: Combination of AI + Robotics and Biological and Chemical Synthetic Engineering
Combination of AI + Robotics and Biological and Chemical Synthetic Engineering to Empower Diverse Industries Medical and Healthcare New New Energy Energy New Full- New Material Design Material Process Bio- Design Drug Chemical Drug Energy Energy Non- R&D Discovery Biopharma -ceutical Biobased Materi
Slide 16: AI+Automation R&D Solutions – Empowering New Sectors
AI+Automation R&D Solutions – Empowering New Sectors • The first fully • First intelligent automated screening platform for the platform for domestic catalyst separation, formulations in screening and the petrochemical testing of active field TCM ingredients in China • Internationally leading cataly
Slide 17: 1H2024 Financial Results
3S xtal?i 1H2024 Financial Results
Slide 18: Sustainable Revenue Growth
Sustainable Revenue Growth Total Revenue RMB’million YOY +30.7% 174.4 133.4 YOY +28.3% 102.6 80.0 2022 2023 23H1 24H1 Confidential Copyright © 18 2024
Slide 19: Revenue Breakdown by Geography and Business Segment
Revenue Breakdown by Geography and Business Segment Revenue by Geographical Location Revenue by Business Segment 23H1 24H1 23H1 24H1 7% 10% 55% 27% 41% 51% 45% 59% 66% 39% Note: Others mainly include European countries, South Korea and Japan. Confidential Copyright © 19 2024
Slide 20: Effective Expense Management and Control
Effective Expense Management and Control R&D Expenses Gen & Admin Expenses RMB’ million Employee benefit expenses Others RMB’ million 480.7 YOY +33.9% YOY +44.8% Excluding non-cash and one-time 296.0 items, YOY +58.3% 359.0 YOY -10.2% 234.3 204.4 234.4 210.4 115.2 101.2 23.4 274.0 209.7 31.9 72.8 14
Slide 21: Effective Expense Management and Control
Effective Expense Management and Control Sales & Mktg Expenses Contract Fulfillment Costs RMB’ million RMB’ million YOY +54.7% YOY +87.5% 126.2 Contract fulfillment costs Excluding non-cash and one- decreased by 4.8% YoY 62.5 time items, YOY +9.6% YOY -4.8% 40.4 67.3 34.6 58.3 55.5 29.6 32.5 29.6 2.
Slide 22: Improved Operating Results - Narrowed Adjusted Net Loss
Improved Operating Results - Narrowed Adjusted Net Loss Adjusted Net Loss (Non-IFRS) RMB’ million 2022 2023 2023H1 2024H1 -251 -358 -437 YOY +29.9% -522 Adjusted net loss narrowed by 30% YoY YOY -19.5% Confidential Copyright © 22 2024
Slide 23: Cash Balance and Operating Cash Flow
Cash Balance and Operating Cash Flow Cash Balance Operating Cash Flow RMB’ million RMB’ million Cash and cash equivalents Term deposits Restricted cash Financial assets at FVTPL YOY +32.3% 567.6 3,841.7 12.8 3,473.7 3,398.0 305.3 429.1 Remained stable 5.4 356.4 2,848.4 1,655.3 299.0 299.3 863.4 2,53
Slide 24: Consolidated Statement of Profit or Loss
Consolidated Statement of Profit or Loss RMB’000 2024H1 2023H1 Revenues 102,630 79,967 Research and development expenses (210,390) (234,421) General and administrative expenses (234,314) (101,165) Contract fulfillment costs (55,478) (58,254) Selling and marketing expenses (34,638) (29,640) Impairmen
Slide 25: Consolidated Balance Sheets
Consolidated Balance Sheets June 30, December 31, June 30, December 31, RMB’000 RMB’000 2024 2023 2024 2023 ASSETS EQUITY AND LIABILITIES Non-current assets Share capital 236 50 Property, plant and equipment Other reserves 12,408,020 (227,110) 357,356 369,887 Accumulated losses (8,292,571) (7,040,34
Slide 26: Q&A Thank you for your listening
Q&A Thank you for your listening Confidential Copyright © 26 2024